224 related articles for article (PubMed ID: 16185181)
1. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Field KM
Pharmacotherapy; 2005 Oct; 25(10):1365-77. PubMed ID: 16185181
[TBL] [Abstract][Full Text] [Related]
2. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.
Arnaud C; Burger F; Steffens S; Veillard NR; Nguyen TH; Trono D; Mach F
Arterioscler Thromb Vasc Biol; 2005 Jun; 25(6):1231-6. PubMed ID: 15790934
[TBL] [Abstract][Full Text] [Related]
3. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
4. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
Albert MA; Staggers J; Chew P; Ridker PM;
Am Heart J; 2001 Jun; 141(6):893-8. PubMed ID: 11376301
[TBL] [Abstract][Full Text] [Related]
5. [Inflammation and C-reactive protein in cardiovascular disease].
Munk PS; Larsen AI
Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1221-4. PubMed ID: 19521445
[TBL] [Abstract][Full Text] [Related]
6. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Li JJ; Fang CH
Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
[TBL] [Abstract][Full Text] [Related]
7. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
[TBL] [Abstract][Full Text] [Related]
8. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein.
Koenig W
Int J Cardiol; 2005 Feb; 98(2):199-206. PubMed ID: 15686768
[TBL] [Abstract][Full Text] [Related]
9. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
Nordestgaard BG; Zacho J
Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
[TBL] [Abstract][Full Text] [Related]
10. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
Sellmayer A; Limmert T; Hoffmann U
Int Angiol; 2003 Mar; 22(1):15-23. PubMed ID: 12771851
[TBL] [Abstract][Full Text] [Related]
11. Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin.
Hu WL; Qiao SB; Li JJ
Cytokine; 2007 Dec; 40(3):201-6. PubMed ID: 18023360
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
[TBL] [Abstract][Full Text] [Related]
13. (TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients.
Noriega V; Pennanen C; Sánchez MP; Chiong M; Llancaqueo M; Lavandero S; Prieto JC
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):211-5. PubMed ID: 19067673
[TBL] [Abstract][Full Text] [Related]
14. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
Goicoechea M; de Vinuesa SG; Lahera V; Cachofeiro V; Gómez-Campderá F; Vega A; Abad S; Luño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
[TBL] [Abstract][Full Text] [Related]
15. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Zhou Z; Rahme E; Pilote L
Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
17. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians.
Windgassen EB; Funtowicz L; Lunsford TN; Harris LA; Mulvagh SL
Postgrad Med; 2011 Jan; 123(1):114-9. PubMed ID: 21293091
[TBL] [Abstract][Full Text] [Related]
18. C-reactive protein: risk assessment in the primary prevention of atherosclerotic disease. Has the time come for including it in the risk profile?
Koenig W
Ital Heart J; 2001 Mar; 2(3):157-63. PubMed ID: 11305526
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
Patrick L; Uzick M
Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071
[TBL] [Abstract][Full Text] [Related]
20. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.
Packard C
Atheroscler Suppl; 2006 Apr; 7(1):21-9. PubMed ID: 16504600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
